Wymac Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 511.00%
- Profit Growth 76.49%
- Ebitda 76.65%
- Net Worth -78.31%
- Total Assets -23.20%
About Wymac Lifesciences
Wymac Lifesciences Private Limited (WLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 April 2018 (Six years and nine months 25 days old ). Its registered office is in Rupnagar, Punjab, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Karanranjit Singh, Harsharan Singh, Vikram Grewal, and Two other members serve as directors at the Company.
Company Details
-
Location
Rupnagar, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999PB2018PTC047786
-
Company No.
047786
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Apr 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Wymac Lifesciences?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karanranjit Singh
|
Director | 19-Apr-2018 | Current |
|
Harsharan Singh
|
Director | 19-Apr-2018 | Current |
|
Vikram Grewal
|
Director | 19-Apr-2018 | Current |
|
Ravneet Kaur
|
Director | 19-Apr-2018 | Current |
|
Dinesh Mehra
|
Director | 19-Apr-2018 | Current |
Financial Performance of Wymac Lifesciences.
Wymac Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 511% increase. The company also saw a substantial improvement in profitability, with a 76.49% increase in profit. The company's net worth observed a substantial decline by a decrease of 78.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wymac Lifesciences?
In 2022, Wymac Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Medville Healthcare Private LimitedKaranranjit Singh, Harsharan Singh and 3 more are mutual person
-
Barqat Cuisines Private LimitedKaranranjit Singh, Harsharan Singh and 1 more are mutual person
-
House Of Barqat Private Limited
Karanranjit Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wymac Lifesciences?
Unlock and access historical data on people associated with Wymac Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wymac Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wymac Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.